Acute Monoblastic Leukemia News

Acute Monoblastic Leukemia	Welcome, Profile Billing Logout

«1 2 345 »

||||||||||  imatinib / Generic mfg., cladribine / Generic mfg., cytarabine / Generic mfg.
Trial completion, Combination therapy:  Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) -  Oct 13, 2013
P1, N=18, Completed,  Sponsor: University of Rochester
Recruiting --> Completed

||||||||||  cytarabine / Generic mfg., decitabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Enrollment change:  Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS (clinicaltrials.gov) -  Oct 8, 2013
P2, N=7, Completed,  Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Completed N=38 --> 7

||||||||||  cytarabine / Generic mfg., decitabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial completion:  Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS (clinicaltrials.gov) -  Oct 8, 2013
P2, N=7, Completed,  Sponsor: Fred Hutchinson Cancer Research Center
N=38 --> 7 Active, not recruiting --> Completed

||||||||||  alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion:  Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) -  Oct 6, 2013
P2, N=25, Completed,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Terminated --> Completed

||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial termination, Combination therapy, Epigenetic controller, Metastases:  Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) -  Sep 17, 2013
P1, N=44, Terminated,  Sponsor: National Cancer Institute (NCI)
Terminated --> Completed Active, not recruiting --> Terminated

||||||||||  Zarnestra (tipifarnib) / Kura Oncology, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial completion:  Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) -  Aug 22, 2013
P2/3, N=2000, Completed,  Sponsor: The University of New South Wales
Active, not recruiting --> Terminated Recruiting --> Completed

|||||||||| Enrollment change, Combination therapy: Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 19, 2013
P1, N=34, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Completed N=24 --> 34

||||||||||  daunorubicin / Generic mfg., clofarabine / Generic mfg.
Trial termination:  Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) -  Aug 12, 2013
P2, N=21, Terminated,  Sponsor: Roswell Park Cancer Institute
N=24 --> 34 Active, not recruiting --> Terminated; Sponsor withdrew support

|||||||||| Enrollment open: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay (clinicaltrials.gov) - Jul 22, 2013
P=N/A, N=15, Recruiting, Sponsor: University of Washington
Active, not recruiting --> Terminated; Sponsor withdrew support Not yet recruiting --> Recruiting

|||||||||| New P1 trial: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 18, 2013
P1, N=30, Recruiting, Sponsor: Stanford University

||||||||||  Zarnestra (tipifarnib) / Kura Oncology
Enrollment change:  Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Jul 9, 2013
P2, N=21, Active, not recruiting,  Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting N=35 --> 21

||||||||||  7-Hydroxystaurosporine (UCN-01) / National Cancer Institute
Trial completion, Combination therapy:  7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes (clinicaltrials.gov) -  Jun 30, 2013
P1, N=30, Completed,  Sponsor: National Cancer Institute (NCI)
N=35 --> 21 Active, not recruiting --> Completed

||||||||||  thioguanine / Generic mfg.
Enrollment change:  Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome (clinicaltrials.gov) -  Jun 25, 2013
P3, N=254, Completed,  Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=158 --> 254

||||||||||  pravastatin / Generic mfg., cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Enrollment open:  Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) -  Jun 25, 2013
P=N/A, N=50, Recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
N=158 --> 254 Not yet recruiting --> Recruiting

||||||||||  MK-8776 / Merck (MSD)
Enrollment open:  Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) -  Jun 12, 2013
P2, N=52, Recruiting,  Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting

||||||||||  Zarnestra (tipifarnib) / Kura Oncology
Enrollment closed:  Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Jun 12, 2013
P2, N=21, Active, not recruiting,  Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting

|||||||||| Enrollment closed: Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 5, 2013
P=N/A, N=98, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting

||||||||||  MK-8776 / Merck (MSD)
New P2 trial:  Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) -  Jun 4, 2013
P2, N=52, Recruiting,  Sponsor: National Cancer Institute (NCI)

||||||||||  bortezomib / Generic mfg.
Trial termination, Combination therapy:  17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer (clinicaltrials.gov) -  Jun 2, 2013
P1, N=74, Terminated,  Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Active, not recruiting Completed --> Terminated

||||||||||  alvocidib (DSP-2033) / Sumitomo Pharma
Trial termination:  Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (clinicaltrials.gov) -  Jun 2, 2013
P1, N=88, Terminated,  Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Active, not recruiting --> Terminated

||||||||||  metformin / Generic mfg., cytarabine / Generic mfg.
New P1 trial:  Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML (clinicaltrials.gov) -  May 6, 2013
P1, N=28, Recruiting,  Sponsor: Northwestern University

|||||||||| Enrollment closed: Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (clinicaltrials.gov) - May 6, 2013
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated Recruiting --> Active, not recruiting

||||||||||  lithium carbonate ER / Generic mfg.
Enrollment open:  Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  May 1, 2013
P1, N=24, Recruiting,  Sponsor: Paolo Caimi, MD
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting

||||||||||  arsenic trioxide / Generic mfg.
New P2 trial:  Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Apr 16, 2013
P2, N=16, Not yet recruiting,  Sponsor: Stanford University

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Trial completion, Combination therapy:  Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders (clinicaltrials.gov) -  Apr 9, 2013
P1, N=25, Completed,  Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Completed

||||||||||  lithium carbonate ER / Generic mfg.
New P1 trial:  Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Mar 27, 2013
P1, N=24, Recruiting,  Sponsor: Paolo Caimi, MD

|||||||||| Enrollment open: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 12, 2013
P1, N=35, Recruiting, Sponsor: University of Southern California
Recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical:  Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) -  Feb 27, 2013
P2, N=47, Active, not recruiting,  Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting

|||||||||| New P1 trial: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 26, 2013
P1, N=35, Recruiting, Sponsor: University of Southern California

||||||||||  MK-2206 / Merck (MSD)
Enrollment closed:  AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Feb 20, 2013
P2, N=43, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

||||||||||  daunorubicin / Generic mfg., imatinib / Generic mfg.
Trial completion, Combination therapy:  Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) -  Feb 11, 2013
P1, N=21, Completed,  Sponsor: The Cleveland Clinic
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  mycophenolate mofetil / Generic mfg.
Trial completion, Post-transplantation:  Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 31, 2013
P2, N=0, Completed,  Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Avastin (bevacizumab) / Roche
Trial termination:  Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 22, 2013
P2, N=120, Terminated,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated; Administratively complete.

||||||||||  Cilcane (cilengitide) / Iceni Pharma
Trial termination:  Cilengitide in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 22, 2013
P2, N=70, Terminated,  Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Administratively complete. Completed --> Terminated; Administratively complete.

||||||||||  Leukine (sargramostim) / Partner Therap, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment change, Combination therapy:  MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia (clinicaltrials.gov) -  Jan 7, 2013
P2, N=24, Completed,  Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Administratively complete. N=30 --> 24

||||||||||  alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion:  Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia (clinicaltrials.gov) -  Jan 7, 2013
P1, N=35, Completed,  Sponsor: National Cancer Institute (NCI)
N=30 --> 24 Terminated --> Completed

||||||||||  Leukine (sargramostim) / Partner Therap, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Combination therapy:  MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia (clinicaltrials.gov) -  Jan 7, 2013
P2, N=24, Completed,  Sponsor: National Cancer Institute (NCI)
Terminated --> Completed Active, not recruiting --> Completed

||||||||||  sorafenib / Generic mfg.
Trial completion:  Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (clinicaltrials.gov) -  Jan 7, 2013
P1, N=48, Completed,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Terminated --> Completed

||||||||||  Zarnestra (tipifarnib) / Kura Oncology
Enrollment change:  Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 3, 2013
P1, N=30, Completed,  Sponsor: National Cancer Institute (NCI)
Terminated --> Completed N=45 --> 30

||||||||||  bortezomib / Generic mfg., daunorubicin / Generic mfg., cytarabine / Generic mfg.
Trial completion:  Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 1, 2013
P2, N=88, Completed,  Sponsor: National Cancer Institute (NCI)
N=45 --> 30 Active, not recruiting --> Completed

|||||||||| Biomarker, Enrollment change: S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 12, 2012
P=N/A, N=357, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed N=230 --> 357

||||||||||  cytarabine / Generic mfg.
Biomarker, Enrollment closed:  S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy (clinicaltrials.gov) -  Dec 12, 2012
P=N/A, N=310, Active, not recruiting,  Sponsor: Southwest Oncology Group
N=230 --> 357 Not yet recruiting --> Active, not recruiting

||||||||||  cytarabine / Generic mfg.
Biomarker, Trial completion:  S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Dec 12, 2012
P=N/A, N=290, Completed,  Sponsor: Southwest Oncology Group
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Completed

|||||||||| Trial completion: S9333A Study of Blood and Bone Marrow Samples From Patients With Previously Untreated Primary Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 12, 2012
P=N/A, N=132, Completed, Sponsor: Southwest Oncology Group
Not yet recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 12, 2012
P=N/A, N=251, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Completed

|||||||||| Trial completion: Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 10, 2012
P3, N=720, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: S0106B Studying Bone Marrow Samples From Women With Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 14, 2012
P=N/A, N=100, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Completed

||||||||||  sorafenib / Generic mfg.
Enrollment change:  Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) -  Nov 7, 2012
P1, N=36, Completed,  Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed N=55 --> 36

||||||||||  Leukine (sargramostim) / Partner Therap
Enrollment change, Metastases:  Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer (clinicaltrials.gov) -  Oct 1, 2012
P1, N=5, Completed,  Sponsor: University of California, San Francisco
N=55 --> 36 N=10 --> 5

||||||||||  Leukine (sargramostim) / Partner Therap
Trial completion, Metastases:  Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer (clinicaltrials.gov) -  Oct 1, 2012
P1, N=5, Completed,  Sponsor: University of California, San Francisco
N=10 --> 5 Active, not recruiting --> Completed



	Diseases Companies Products Productz Mechanisms of Action Sites